A first patient has been dosed in a Phase 1 clinical trial investigating the small molecule inhibitor EPI-7386 as a treatment for metastatic castration-resistant prostate cancer (CRPC), its developer, ESSA Pharma, reported. Metastatic CRPC is prostate cancer that has metastasized, or spread to distant regions, and is resistant to traditional treatments that lower levels of androgen hormones, like testosterone. Recruitment for this open-label trial (NCT04421222) testing four doses of the oral candidate, is underway at three U.S.…
You must be logged in to read/download the full post.
The post Phase 1 Trial of Oral Treatment for Metastatic CRPC Doses First Patient appeared first on BioNewsFeeds.